Market Research Logo

Bacterial Vaginosis - Pipeline Review, H1 2015

Bacterial Vaginosis - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Bacterial Vaginosis - Pipeline Review, H1 2015’, provides an overview of the Bacterial Vaginosis’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Bacterial Vaginosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bacterial Vaginosis and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Bacterial Vaginosis
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Bacterial Vaginosis and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Bacterial Vaginosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Bacterial Vaginosis pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Bacterial Vaginosis
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Bacterial Vaginosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Bacterial Vaginosis Overview
Therapeutics Development
Pipeline Products for Bacterial Vaginosis - Overview
Pipeline Products for Bacterial Vaginosis - Comparative Analysis
Bacterial Vaginosis - Therapeutics under Development by Companies
Bacterial Vaginosis - Therapeutics under Investigation by Universities/Institutes
Bacterial Vaginosis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Bacterial Vaginosis - Products under Development by Companies
Bacterial Vaginosis - Products under Investigation by Universities/Institutes
Bacterial Vaginosis - Companies Involved in Therapeutics Development
AmVac AG
Osel Inc.
Starpharma Holdings Limited
Valeant Pharmaceuticals International, Inc.
Bacterial Vaginosis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMV-100 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
astodrimer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
benzoyl peroxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LACTIN-V - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide for Bacterial Vaginosis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Product-55394 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
secnidazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bacterial Vaginosis - Recent Pipeline Updates
Bacterial Vaginosis - Dormant Projects
Bacterial Vaginosis - Discontinued Products
Bacterial Vaginosis - Product Development Milestones
Featured News & Press Releases
Sep 09, 2014: Symbiomix Therapeutics Makes First Corporate Announcement: Completion of Enrollment in a Phase 2 Clinical Trial of SYM-1219 for Bacterial Vaginosis
Jul 14, 2014: FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial
Apr 03, 2013: Starpharma Announces Positive Results From Phase II Study Of VivaGel For Prevention Of Recurrent Bacterial Vaginosis
Nov 28, 2012: Starpharma Announces Results From Two Phase III Studies Of VivaGel For Treatment Of Bacterial Vaginosis
Oct 18, 2012: Starpharma Completes Recruitment In Two Phase III Trials Of VivaGel For Treatment For Bacterial Vaginosis
Jun 25, 2012: Starpharma Completes Patient Recruitment For Phase II And First Pivotal Phase III Trials Of VivaGel
Jun 04, 2012: Starpharma Completes 60% Patient Recruitment For Phase III Trials Of VivaGel
Jan 11, 2012: Starpharma Receives FDA Special Protocol Assessment For Phase III Trials Of VivaGel For Treatment Of Bacterial Vaginosis
Nov 21, 2011: Starpharma Secures European Agreement On BV Phase III Treatment
Oct 10, 2011: Starpharma Secures FDA Agreement On Phase III VivaGel Bacterial Vaginosis Treatment Program
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Bacterial Vaginosis, H1 2015
Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Bacterial Vaginosis - Pipeline by AmVac AG, H1 2015
Bacterial Vaginosis - Pipeline by Osel Inc., H1 2015
Bacterial Vaginosis - Pipeline by Starpharma Holdings Limited, H1 2015
Bacterial Vaginosis - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Bacterial Vaginosis Therapeutics - Recent Pipeline Updates, H1 2015
Bacterial Vaginosis - Dormant Projects, H1 2015
Bacterial Vaginosis - Discontinued Products, H1 2015
List of Figures
Number of Products under Development for Bacterial Vaginosis, H1 2015
Number of Products under Development for Bacterial Vaginosis - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report